BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 28208660)

  • 1. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
    Abou-Fay├žal C; Hatat AS; Gazzeri S; Eymin B
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
    Matalkah F; Martin E; Zhao H; Agazie YM
    Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in nitrogen-containing heterocyclic compounds as receptor tyrosine kinase inhibitors for the treatment of cancer: Biological activity and structural activity relationship.
    Taruneshwar Jha K; Shome A; Chahat ; Chawla PA
    Bioorg Chem; 2023 Sep; 138():106680. PubMed ID: 37336103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment.
    Ghosh S; Marrocco I; Yarden Y
    Adv Cancer Res; 2020; 147():1-57. PubMed ID: 32593398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis-New insight and futuristic vision.
    Huang XL; Khan MI; Wang J; Ali R; Ali SW; Zahra QU; Kazmi A; Lolai A; Huang YL; Hussain A; Bilal M; Li F; Qiu B
    Int J Biol Macromol; 2021 Jun; 180():739-752. PubMed ID: 33737188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
    Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer.
    Donzelli S; Cioce M; Muti P; Strano S; Yarden Y; Blandino G
    Semin Cell Dev Biol; 2016 Feb; 50():133-42. PubMed ID: 26773212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases.
    Chen MK; Hung MC
    FEBS J; 2015 Oct; 282(19):3693-721. PubMed ID: 26096795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
    Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y
    Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.
    Tolmachev V; Stone-Elander S; Orlova A
    Lancet Oncol; 2010 Oct; 11(10):992-1000. PubMed ID: 20667780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flavonoids as RTK inhibitors and potential anticancer agents.
    Teillet F; Boumendjel A; Boutonnat J; Ronot X
    Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond the vascular endothelial growth factor axis: update on role of imaging in nonantiangiogenic molecular targeted therapies in oncology.
    Howard SA; Rosenthal MH; Jagannathan JP; Krajewski KM; Shinagare AB; Ramaiya NH; Tirumani SH
    AJR Am J Roentgenol; 2015 May; 204(5):919-32. PubMed ID: 25905926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive responses to antibody based therapy.
    Rodems TS; Iida M; Brand TM; Pearson HE; Orbuch RA; Flanigan BG; Wheeler DL
    Semin Cell Dev Biol; 2016 Feb; 50():153-63. PubMed ID: 26808665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders.
    Nelson KN; Peiris MN; Meyer AN; Siari A; Donoghue DJ
    Trends Mol Med; 2017 Jan; 23(1):59-79. PubMed ID: 27988109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of receptor tyrosine kinase activation in cancer.
    Du Z; Lovly CM
    Mol Cancer; 2018 Feb; 17(1):58. PubMed ID: 29455648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases.
    Shimizu M; Adachi S; Masuda M; Kozawa O; Moriwaki H
    Mol Nutr Food Res; 2011 Jun; 55(6):832-43. PubMed ID: 21538846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RTKs in pathobiology of head and neck cancers.
    Nadhan R; Srinivas P; Pillai MR
    Adv Cancer Res; 2020; 147():319-373. PubMed ID: 32593405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.